Chicago, IL-based venture capital firm Arch Venture Partners closed Arch Venture Fund XI, at over $1.85 billion.
The new fund will invest in the creation and funding of early stage biotechnology companies.
Arch will invest Fund XI in early stage biotechnology companies working on infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools, data sciences, and ways of reimagining diagnostics and therapies. The firm continues to take a special interest in how healthcare is delivered to patients – from data collection to therapeutics manufacturing to direct patient care. Arch will also examine areas exposed by the pandemic where innovation can solve challenges such as vaccine distribution, medical professionals being overworked and understaffed, and the scarcity of quality mental health services.
The Managing directors’ team include:
- Robert Nelsen
- Keith Crandell
- Kristina Burow
- Mark McDonnell
- Steve Gillis
- Paul Berns, previously a Venture Partner, who has been named a Managing Director;
In addition, Jay Markowitz joined as a Senior Partner, Carol Suh and Sean Kendall have been named Principals and Corey Ritter and Nilay Thakar were both promoted to Senior Associate.